Healthcare Industry News: Allergan
News Release - November 8, 2007
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate StrategySAN FRANCISCO, Nov. 8 (HSMN NewsFeed) -- Jennerex, Inc. today announced the addition of Mr. Robert A. Ingram as Special Advisor to the Chairman and to The President & CEO, and the hiring of Mr. Marty Glick as Executive Vice President, Corporate Strategy.
Bob Ingram is Vice Chairman, Pharmaceuticals at GlaxoSmithKline (plc), and previously served as Chief Executive Officer, Chief Operating Officer and President of Pharmaceutical operations for Glaxo Wellcome. Mr. Ingram is Chairman of the Board of Directors of OSI Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, and a member of the Board of Directors of Allergan, Inc., Lowe's Companies, Edwards Lifesciences Corporation, and Wachovia Corporation.
"We are delighted to welcome Bob to the Jennerex team. His experience in leading companies which have successfully developed and commercialized major new medicines adds significant strategic depth to our team," said Brennan Mulcahy, Chairman of Jennerex.
"I am excited to work with the Board and CEO of Jennerex to develop and commercialize a new class of biotherapeutics for the treatment of several major types of cancer," said Bob Ingram.
"We know Bob's extensive pharmaceutical leadership experience will be invaluable to Jennerex as we leverage our innovative technology platform to develop and commercialize major new medicines to treat patients with serious unmet needs in oncology, including liver cancer, melanoma and lung cancer," said David H. Kirn, M.D., President and Chief Executive Officer.
Mr. Glick was Executive Vice President and Chief Financial Officer of Theravance, Inc. until 2005. He led the efforts to successfully raise over $350 million of private and public equity and to form an innovative strategic alliance with GlaxoSmithKline. Prior to Theravance, Mr. Glick held the position of Vice President Finance at Genentech Inc where he was involved in structuring major deals such as in-licensing of RituxanŽ from Idec (now Biogen Idec). Marty was also a co-founder and Board member of Eyetech Pharmaceuticals.
"Marty's experience in working with top management to successfully finance and build emerging biopharmaceutical companies is an important addition to our team as we drive our lead product candidate toward late stage clinical development and commercialization," said Dr. Kirn.
Jennerex Biotherapeutics is a clinical stage biotherapeutics company working to create, develop and commercialize first-in-class cancer products. Our products are engineered viruses that have been modified to be safe and effective against various forms of cancer. Jennerex products kill cancer by targeting, attacking and eradicating cancer cells. Our lead product candidate, JX-594, has demonstrated clear anti-cancer effects in a Phase 1 study in patients with late-stage liver cancer. Jennerex has initiated a Phase 2a clinical trial in the U.S., for liver cancer and is currently enrolling a Phase 2a clinical trial at several sites in the U.S. for metastatic melanoma. Jennerex is also planning a Phase 1 study with IV administration focusing on lung cancer and melanoma.
For more information about Jennerex, please visit http://www.jennerex.com.
Source: Jennerex Biotherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.